section name header

Pronunciation

fen-ox-ee-BEN-za-meen

Classifications

Therapeutic Classification: antihypertensives

Pharmacologic Classification: alpha adrenergic blockers

Indications

REMS


Unlabeled Use:

Action

  • Produces long-lasting blockade of alpha-adrenergic receptors in smooth muscle and exocrine glands.
  • Blocks epinephrine- and norepinephrine-induced vasoconstriction, resulting in hypotension and tachycardia.
Therapeutic effects:
  • Reduction of symptoms of pheochromocytoma.

Pharmacokinetics

Absorption: Variably absorbed from the GI tract.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized by the liver.

Half-Life: 24 hr.

Time/Action Profile

(alpha-adrenergic blockade)

ROUTEONSETPEAKDURATION
PO1–4 hr1 wk3–4 days





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, angina, HF, tachycardia

EENT: miosis, nasal congestion

GI: diarrhea, dry mouth, nausea, vomiting

GU: inhibition of ejaculation

Neuro: confusion, dizziness, drowsiness, headache, malaise, sedation, tiredness, weakness

Interactions

Drug-drug:

Route/Dosage

Dosage requires individual titration

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Dibenzyline